Review



epidermal growth factor receptor egfr signaling proteins  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc epidermal growth factor receptor egfr signaling proteins
    Worse prognosis of non-responders in arm Cam+TPF (A) Spatial heatmaps showing expression intensity of <t>EGFR</t> , including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 2); scale bar, 5 mm. (B) Dot plot showing expression levels of genes related to EGFR signaling pathway, including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 2). (C) Heatmap showing the quantitative immunohistochemical results of post-therapy EGFR and downstream proteins in non-responders in arm Cam+TPF compared with arm Cam, including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 7). (D) Follow-up of the two non-responders in arm Cam+TPF. Red circle indicates primary tumor, red arrow indicates tumor metastasis. <t>EGFR,</t> <t>epidermal</t> growth factor receptor; CT, computed tomography; MRI, magnetic resonance imaging; PET-CT, positron emission tomography and computed tomography.
    Epidermal Growth Factor Receptor Egfr Signaling Proteins, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 225 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/epidermal growth factor receptor egfr signaling proteins/product/Cell Signaling Technology Inc
    Average 95 stars, based on 225 article reviews
    epidermal growth factor receptor egfr signaling proteins - by Bioz Stars, 2026-02
    95/100 stars

    Images

    1) Product Images from "Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial"

    Article Title: Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial

    Journal: Cell Reports Medicine

    doi: 10.1016/j.xcrm.2025.101930

    Worse prognosis of non-responders in arm Cam+TPF (A) Spatial heatmaps showing expression intensity of EGFR , including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 2); scale bar, 5 mm. (B) Dot plot showing expression levels of genes related to EGFR signaling pathway, including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 2). (C) Heatmap showing the quantitative immunohistochemical results of post-therapy EGFR and downstream proteins in non-responders in arm Cam+TPF compared with arm Cam, including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 7). (D) Follow-up of the two non-responders in arm Cam+TPF. Red circle indicates primary tumor, red arrow indicates tumor metastasis. EGFR, epidermal growth factor receptor; CT, computed tomography; MRI, magnetic resonance imaging; PET-CT, positron emission tomography and computed tomography.
    Figure Legend Snippet: Worse prognosis of non-responders in arm Cam+TPF (A) Spatial heatmaps showing expression intensity of EGFR , including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 2); scale bar, 5 mm. (B) Dot plot showing expression levels of genes related to EGFR signaling pathway, including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 2). (C) Heatmap showing the quantitative immunohistochemical results of post-therapy EGFR and downstream proteins in non-responders in arm Cam+TPF compared with arm Cam, including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 7). (D) Follow-up of the two non-responders in arm Cam+TPF. Red circle indicates primary tumor, red arrow indicates tumor metastasis. EGFR, epidermal growth factor receptor; CT, computed tomography; MRI, magnetic resonance imaging; PET-CT, positron emission tomography and computed tomography.

    Techniques Used: Expressing, Immunohistochemical staining, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography-Computed Tomography, Positron Emission Tomography



    Similar Products

    epidermal growth factor receptor egfr signaling proteins  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc epidermal growth factor receptor egfr signaling proteins
    Worse prognosis of non-responders in arm Cam+TPF (A) Spatial heatmaps showing expression intensity of <t>EGFR</t> , including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 2); scale bar, 5 mm. (B) Dot plot showing expression levels of genes related to EGFR signaling pathway, including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 2). (C) Heatmap showing the quantitative immunohistochemical results of post-therapy EGFR and downstream proteins in non-responders in arm Cam+TPF compared with arm Cam, including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 7). (D) Follow-up of the two non-responders in arm Cam+TPF. Red circle indicates primary tumor, red arrow indicates tumor metastasis. <t>EGFR,</t> <t>epidermal</t> growth factor receptor; CT, computed tomography; MRI, magnetic resonance imaging; PET-CT, positron emission tomography and computed tomography.
    Epidermal Growth Factor Receptor Egfr Signaling Proteins, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/epidermal growth factor receptor egfr signaling proteins/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    epidermal growth factor receptor egfr signaling proteins - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Worse prognosis of non-responders in arm Cam+TPF (A) Spatial heatmaps showing expression intensity of EGFR , including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 2); scale bar, 5 mm. (B) Dot plot showing expression levels of genes related to EGFR signaling pathway, including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 2). (C) Heatmap showing the quantitative immunohistochemical results of post-therapy EGFR and downstream proteins in non-responders in arm Cam+TPF compared with arm Cam, including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 7). (D) Follow-up of the two non-responders in arm Cam+TPF. Red circle indicates primary tumor, red arrow indicates tumor metastasis. EGFR, epidermal growth factor receptor; CT, computed tomography; MRI, magnetic resonance imaging; PET-CT, positron emission tomography and computed tomography.

    Journal: Cell Reports Medicine

    Article Title: Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial

    doi: 10.1016/j.xcrm.2025.101930

    Figure Lengend Snippet: Worse prognosis of non-responders in arm Cam+TPF (A) Spatial heatmaps showing expression intensity of EGFR , including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 2); scale bar, 5 mm. (B) Dot plot showing expression levels of genes related to EGFR signaling pathway, including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 2). (C) Heatmap showing the quantitative immunohistochemical results of post-therapy EGFR and downstream proteins in non-responders in arm Cam+TPF compared with arm Cam, including Cam+TPF-pNR group ( n = 2) and Cam-pNR group ( n = 7). (D) Follow-up of the two non-responders in arm Cam+TPF. Red circle indicates primary tumor, red arrow indicates tumor metastasis. EGFR, epidermal growth factor receptor; CT, computed tomography; MRI, magnetic resonance imaging; PET-CT, positron emission tomography and computed tomography.

    Article Snippet: Tumor biopsy and surgical samples were collected and examined for a panel of checkpoint molecules, immunocyte subsets and epidermal growth factor receptor (EGFR) signaling proteins using immunohistochemistry, including EGFR (CST, D38B1, 4267S, 1:400), p -EGFR (Tyr1068) (CST, 2234S, 1:200), p -p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (CST, D13.14.4E, 4370S, 1:200), p -p38 MAPK (Thr180/Tyr182) (CST, D3F9, 4511S, 1:200), p -Akt (Ser473) (CST, D9E, 4060S, 1:200), CD3ε (CST, D7A6E, 85061S, 1:200), CD4 (Abcam, ab133616, 1:400), CD8α (CST, D8A8Y, 85336S, 1:400), CD14 (Abcam, ab182032, 1:400), CD68 (CST, D4B9C, 76437S, 1:400), CD11b (CST, D6X1N, 49420S, 1:200), CD11c (Abcam, ab52632, 1:200), CD20 (Abcam, ab64088, 1:200), Foxp3 (CST, D2W8E, 98377S, 1:100), CD56 (CST, 123C3, 3576S, 1:100), TIM-3 (CST, D5D5R, 45208S, 1:50), TIGIT (Abcam, ab243903, 1:200), PD-1 (CST, EH33, 43248S, 1:100).

    Techniques: Expressing, Immunohistochemical staining, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography-Computed Tomography, Positron Emission Tomography